NASDAQ$VYNE
VYNE Therapeutics INC · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis and promising preclinical data for VYN201, completed the divestiture of topical minocycline franchise
VYNE Therapeutics reported financial results for Q1 2022, highlighting progress with FMX114 and VYN201. The company reported positive Phase 1b data for FMX114 and promising preclinical data for VYN201. They also completed the divestiture of their topical minocycline franchise.
- Reported positive Phase 1b safety and efficacy data for FMX114 in mild-to-moderate atopic dermatitis.
- Released promising preclinical data for VYN201.
- Completed the divestiture of the topical minocycline franchise.
- Anticipates cash, cash equivalents and restricted cash as of March 31, 2022 will be sufficient to fund its operations through at least the first quarter of 2023.
Headline financials
Revenue & EPS history
VYNE · Revenue · Quarterly
$178K
Revenue by segment
VYNE · $86K total across 1 segment · Q1 2026
- Royalty revenues$86K—100.0%
Forward guidance
VYNE anticipates that its cash, cash equivalents and restricted cash as of March 31, 2022 will be sufficient to fund its operations through at least the first quarter of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
-1.0%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-10.8%
Avg return
30 days after
52%
17 / 33 earnings
Positive
+23.0%
Q4 2021
Best reaction
-38.4%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | — | — | |
| Q4 2025 | +1.0% | -0.2% | -0.5% | |
| Q2 2025 | +0.6% | -4.3% | -10.6% | |
| Q1 2025 | -2.4% | -20.0% | -28.1% | |
| Q4 2024 | -2.5% | -21.3% | -34.7% | |
| Q3 2024 | +1.0% | -4.2% | -14.4% | |
| Q2 2024 | +8.8% | +8.2% | +7.6% | |
| Q1 2024 | -1.8% | +6.3% | -17.3% | |
| Q4 2023 | -4.7% | -3.4% | +31.8% | |
| Q3 2023 | +1.7% | +11.4% | -23.1% | |
| Q2 2023 | -11.8% | -13.7% | -26.7% | |
| Q1 2023 | +20.9% | +17.9% | -11.9% | |
| Q4 2022 | -14.7% | -21.2% | -11.1% | |
| Q3 2022 | +9.7% | +0.0% | -15.4% | |
| Q2 2022 | +5.3% | +12.5% | -4.6% | |
| Q1 2022 | +5.0% | +8.2% | +27.2% | |
| Q4 2021 | +23.0% | +28.7% | -8.0% | |
| Q3 2021 | -1.5% | -5.9% | +10.3% | |
| Q2 2021 | -38.4% | -42.9% | -45.7% | |
| Q1 2021 | -19.7% | -24.9% | -15.4% | |
| Q4 2020 | -9.7% | -6.5% | -6.5% | |
| Q3 2020 | -2.6% | +0.6% | -1.2% | |
| Q2 2020 | -12.5% | -12.2% | -26.8% | |
| Q1 2020 | -7.2% | -13.3% | +7.2% | |
| Q4 2019 | +5.8% | +42.6% | -9.3% | |
| Q3 2019 | +4.4% | +2.6% | -21.3% | |
| Q2 2019 | -8.7% | -16.4% | +29.8% | |
| Q1 2019 | -1.3% | -2.3% | -4.5% | |
| Q4 2018 | +0.5% | +0.2% | -7.3% | |
| Q3 2018 | +1.7% | +0.0% | -17.8% | |
| Q2 2018 | +3.4% | -2.7% | -5.9% | |
| Q1 2018 | +9.2% | +7.2% | -11.9% | |
| Q4 2017 | +4.8% | +2.9% | -78.1% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro